Posted in | News | Nanomedicine

WaferGen Announces Successful Demonstration of SmartChip System

WaferGen Biosystems, Inc. (OTC:WGBS) (BULLETIN BOARD: WGBS) , a leading developer of state-of-the-art gene expression, genotyping, cell biology and stem cell research systems, today announced that academic researchers have successfully demonstrated the performance of the company's SmartChip(TM) Real-Time PCR System in the initial phase of the platform's ongoing alpha testing program. Initial tests conducted at the University of Pittsburgh School of Medicine have demonstrated a number of the SmartChip system's key analytical specifications, showing the product's complete workflow on 1,000 oncology genes using small amounts of samples from emphysema, idiopathic pulmonary fibrosis (IPF) and healthy patients.

Key workflow elements that have been successfully demonstrated include primer-ready SmartChips and the drying and reconstitution of primers for rapid high-throughput 100 nL real-time polymerase chain reaction (PCR). Additionally, the platform's ability to perform PCR in nano-volumes without any pre-amplification has been demonstrated using various control genes, as well as indicators of other genes that are known to be expressed in patient samples. The next phase of the alpha testing program will focus on using the SmartChip system to identify biomarkers of interest. Upon completion of the ongoing alpha testing program, data will be presented and/or published in appropriate academic venues.

"The successful demonstration of the performance of the revolutionary SmartChip system in a rigorous research setting is a tremendous step forward for this novel platform. We are particularly excited that the platform has shown the ability to capture the expression of genes that have not been able to be seen using microarrays," stated Alnoor Shivji, WaferGen's chairman and chief executive officer. "We expect that this is just the first milestone related to the SmartChip alpha testing program and look forward to new findings on biomarker discovery and validation."

The SmartChip alpha testing program involves the study of RNA isolated from lung tissue samples from healthy patients, as well as patients with chronic obstructive pulmonary disease (COPD) and IPF. Researchers are screening these RNA samples with the SmartChip Real-Time PCR System in order to assess the platform's performance in conducting novel gene expression research.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    WaferGen Biosystems, Inc.. (2019, February 15). WaferGen Announces Successful Demonstration of SmartChip System. AZoNano. Retrieved on April 15, 2024 from

  • MLA

    WaferGen Biosystems, Inc.. "WaferGen Announces Successful Demonstration of SmartChip System". AZoNano. 15 April 2024. <>.

  • Chicago

    WaferGen Biosystems, Inc.. "WaferGen Announces Successful Demonstration of SmartChip System". AZoNano. (accessed April 15, 2024).

  • Harvard

    WaferGen Biosystems, Inc.. 2019. WaferGen Announces Successful Demonstration of SmartChip System. AZoNano, viewed 15 April 2024,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.